Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MERTK | Q12866 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450608 | 0.83 | POLB (0.60) | POLBBRAFRIPK1EPHX1RAB9A | |
| SCHEMBL13595613 | 0.80 | EPHX1 (0.72) | POLBEPHX1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4527096 | 0.79 | NPC1 (0.53) | POLBRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL14860966 | 0.79 | EPHX1 (0.70) | POLBEPHX1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4962243 | 0.76 | PRMT3 (0.70) | POLBEPHX1RAB9ANPC1EPHX2 | |
| SCHEMBL4962163 | 0.76 | PRMT3 (0.70) | POLBEPHX1RAB9ANPC1EPHX2 | |
| SCHEMBL6724549 | 0.75 | RAB9A (0.80) | POLBEPHX1RAB9ANPC1EPHX2 | |
| SCHEMBL29450622 | 0.74 | KMT2A (0.54) | POLBEPHX1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13198107 | 0.73 | MAPK14 (0.64) | POLBEPHX1RAB9ANPC1EPHX2 | |
| SCHEMBL13198112 | 0.73 | MAPK14 (0.64) | POLBEPHX1RAB9ANPC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | claimed |
| EP-1689717-B1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LTD (GB) | 2007-12-26 | — | — | EP | claimed |
| EP-1689717-A1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | claimed |
| WO-2005049576-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1689717-B1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LTD (GB) | 2007-12-26 | — | — | EP | disclosed |
| EP-1689717-A1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049576-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | HRH4, NR1H2, NR1H3 | POLB 1028/4885BRAF 2473/4885RIPK1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.